Market Notices

Publicerat: 2019-03-25 11:00:05

Spotlight: Market notice 68/19 - Information regarding the rights issue from Double Bond Pharmaceutical International AB

The last day of trading in the company’s shares (DBP B) including the right to receive unit rights is March 28, 2019. The first day excluding the right to obtain the rights is March 29, 2019.

The last day of trading in the company’s shares (DBP B) including the right to receive unit rights is March 28, 2019. The first day excluding the right to obtain the rights is March 29, 2019.

One share entitles the owner to one (1) unit right. Fourteen (14) unit rights entitles the owner to subscribe for one (1) unit at the price of SEK 6,00. One unit consists of one (1) new share and one (1) free subscription option (1:14 á 6,00 SEK).  

Trading with unit rights will take place from April 3, 2019 until April 24, 2019 on Spotlight Stock Market.  

Trading with the paid subscribed units will take place from April 3, 2019 until the registration of the issue at Bolagsverket.  

The subscription period lasts from April 3, 2019 to April 26, 2019. 

Information about the unit right:  
Shortname: DBP UR B 
ISIN-code: SE0012455582 
Orderbook-ID: 535F
CFI: RSSXXR
FISN: DOUBLEBOND/SUBS RTS NL PD 
First day of trading: April 3, 2019
Last day of trading: April 24, 2019 
Market Segment: SPSE
MIC Code: XSAT 
Tick table/liquidity band #: A (Other instruments) 

Information about the paid subscribed unit:    
Shortname: DBP BTU B 
ISIN-code: SE0012455590 
Orderbook-ID: 535E
CFI: MCMUXR
FISN: DOUBLEBOND/UT 1 AK + 1 TO 
Trading period: April 3, 2019 until the registration of the issue at Bolagsverket.  
Market Segment: SPSE
MIC Code: XSAT
Tick table/liquidity band #: A (Other instruments) 

Please be advised that if the rights issue give rise to a conversion factor, all overnight orders in the company’s orderbook will be deleted. If so this will occur after closing on March 28, 2019. 

Stockholm March 25, 2019

Spotlight Stock Market
08-511 68 000
info@spotlightstockmarket.com 



Läs mer hos Cision
Läs mer om Double Bond Pharmaceutical International AB